Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$79,819.00-0.45%ETH$2,312.62-0.50%GOLD$4,022.70-0.39%OIL$100.95-0.80%
Smart Investors Daily
SID Premium
CL

NASDAQ · CLGN

CollPlant Biotechnologies Ltd.

Healthcare · Biotechnology

$3.75

Up+$0.08 (+2.18%)

Updated Oct 27, 2026, 10:21 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
23.78M
P/E ratio
-1.96
Dividend yield
0.00%
52-week range
$0.26 – $9.60
Volume
33.81K
Avg. volume
99.32K

Price performance · CLGN

CLGN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

CLGN closed at $3.75 after 21 trading sessions, down 3.10% for the selected period.

Last close
$3.75
Period change
-3.10%
Period low
$3.39
Period high
$4.13
Daily close
View OHLC price history
CLGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$3.67$3.91$3.65$3.7533.81K
Oct 23, 2026$3.60$3.72$3.52$3.6712.1K
Oct 22, 2026$3.71$3.74$3.41$3.6210.6K
Oct 21, 2026$3.80$3.81$3.551$3.7559.68K
Oct 20, 2026$3.5703$3.88$3.5302$3.8820.36K
Oct 19, 2026$3.62$3.68$3.45$3.5628.97K
Oct 16, 2026$3.70$3.719$3.53$3.62513.44K
Oct 15, 2026$4.01$4.01$3.5901$3.6872.29K
Oct 14, 2026$4.00$4.13$3.82$4.1339.86K
Oct 13, 2026$4.05$4.11$3.85$3.9148K
Oct 12, 2026$3.50$4.45$3.50$4.02166.79K
Oct 9, 2026$3.88$4.126$3.51$3.51182.35K
Oct 8, 2026$3.49$4.16$3.31$3.9757.51K
Oct 7, 2026$3.35$3.585$3.31$3.4623.06K
Oct 6, 2026$3.39$3.4899$3.25$3.3925.02K
Oct 5, 2026$3.49$3.67$3.4006$3.417.51K
Oct 2, 2026$3.62$3.62$3.30$3.4645.5K
Oct 1, 2026$3.84$3.84$3.55$3.5726.27K
Sep 30, 2026$3.825$3.83$3.70$3.7810.93K
Sep 29, 2026$3.94$3.94$3.68$3.7921.27K
Sep 28, 2026$4.26$4.30$3.7497$3.8731.26K

Latest CLGN news

The latest Smart Investors Daily articles mentioning CLGN.

Stock researchCompany · Overview

CLGN research

Overview

Company profile and research snapshot.

Company profile

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.50
Implied upside
—
Analysts
—
CLGN recent ratings
DateFirmRatingTarget
Feb 6, 2026D. Boral CapitalHold—
Nov 28, 2025D. Boral CapitalBuy—
Oct 20, 2025D. Boral CapitalBuy—
Sep 16, 2025D. Boral CapitalBuy—
Aug 21, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 9, 2026

COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT

CollPlant Biotechnologies (Nasdaq: CLGN), an innovative technology company operating at the intersection of deep-tech photonic computing and biotechnology today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 989,301 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof) and unregistered warrants to purchase up to 1,483,952 ordinary shares in a private placement at a combined purchase price of $3.74 per ordinary shar

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By